Factors Affecting the Receipt of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) among Diabetic Patients at Kantharalak Hospital in Sisaket
Article Sidebar
Main Article Content
Abstract
Objective: To determine the proportion of type 2 diabetic patients receiving Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) and to investigate factors affecting the receipt of those medications. Method: This cross sectional study collected the data on gender, age, occupation, health benefit scheme, comorbidities, microalbuminuria levels and the receipt of ACEI or ARB from medical records of 3,221 type 2 diabetic patients seeking care from outpatient department or diabetic clinic at Kantharalak Hospital during 2013-2014. Results: 1,248 from 3,221 type 2 diabetic patients (38.8%) received ACEI or ARB. 20.8% of those with no comorbidities received the medications, while 69.0% of those with hypertension received the medications. Men were 1.4 times more likely than female to receive the medications (95%CI=1.14-1.61). Patients older than 50 years were more likely than those younger than 40 years to receive the medications with odds ratio=2.66-3.62, depending on patient age. Having hypertension as comorbidity was significantly related to the receipt of those medications with odds ratio= 2.45 (95%CI=1.83-3.29). Positive test of microalbuminuria (≥15 mg/dL) and health benefit scheme were not associated with the receipt of those medications. Conclusion: The hospital should increase the prescribing rate of ACEI and ARB in type 2 diabetic patients. In addition, it should improve the test of microalbuminuria in order to give more useful information for prescribing decision on these medications.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
2. Aekplakorn W, Chariyalertsak S, Kessomboon P, Sangthong R, Inthawong R, Putwatana P, et al. Prevalence and management of diabetes and metabolic risk factors in Thai adults: the Thai National Health Examination Survey IV. Diabetes Care 2009; 34:1980-5.
3. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33 Suppl1:S4-10.
4. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351:1952-61.
5. Sukchan P, Uaarayaporn. The coverage and quality of health services for diabetic mellitus patient in Songkhla hospital, Sonkhla province. Princess of Naradhiawas University Journal. 2556; 5:325-36.
6. Rangsin R, Angkasuwapla N, Medical Research Network. An assessment on quality of care among patients diagnosed with type 2 diabetes and hypertension visiting hospitals of Ministry of Public Health and bangkok metropolitan Administration in Thailand, 2012. Bangkok: National Health Security Office; 2012.
7. Augtametagul P. Drug utilization evaluation of Cefoperazone/Sulbactam in a general hospital. Thai Journal of Pharmacy Practice 2014; 6: 77-83.
